EXEL: Multiplikator rega marang pendapatan Exelixis Inc

Simbol lan logo merek Exelixis Inc (EXEL)

Steady demand for Cabometyx generates a reliable cash flow, supporting the historical P/S ratio for Exelixis, Inc. (EXEL). The 6.90 metric confirms the current valuation level. Financial independence from debt is based on revenues from the flagship drug, while the integration of ESG standards ensures the ethics of research and the environmental safety of drug production.

EXEL Kapitalisasi marang pendapatan Exelixis Inc. (04.07.2022 - 13.11.2026)

Rincian analitis perusahaan Exelixis Corp (EXEL)

- rega saham lan konsensus proyeksi valuasi:
Bagan owah-owahan rega exelixis.com|EXEL - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar Exelixis Corp|EXEL - Nilai Perusahaan
- data kapitalisasi buku:
Nilai Aset Bersih saben Saham Exelixis|EXEL - Aset Bersih Perusahaan|Multiplikator Kapitalisasi Pasar marang Nilai Buku exelixis.com|EXEL - Total Aset Perusahaan
- statistik kawajiban utang lan likuiditas:
Utang marang Modal Exelixis, Inc.|EXEL - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang modal Exelixis Inc.|EXEL - Gunggung utang perusahaan|Rasio utang marang aset resik Exelixis Corp|EXEL - Kewajiban jangka dawa perusahaan|Gedhene kewajiban jangka cendhak Exelixis|Rasio jangkoan perantara exelixis.com
- data bathi lan kelipatan valuasi:
EXEL - Bathi resik|Bathi resik sing dikarepake Exelixis, Inc.|EXEL - Rasio rega marang bathi|Pangali mangsa ngarep rega marang bathi Exelixis Inc|EXEL - Pangali PEG|Pangali EV/EBITDA Exelixis Corp|EXEL - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben siji saham sajrone 12 wulan pungkasan Exelixis|EXEL - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan exelixis.com|EXEL - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Exelixis, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
EXEL - Dodolan perusahaan|Prakiraan pendapatan perusahaan exelixis.com|EXEL - Multiplikator P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Exelixis Corp
Ringkesan analitik perusahaan:exelixis.com, EXEL
Produk seri exelixis.com

The ratio of market capitalization to annual sales determines the value of each dollar of revenue, allowing for an assessment of whether market pricing is fair under tight monetary policy. For Exelixis, Inc. (EXEL), which depends on a single drug, the revenue multiple trend serves as an indicator of investor sensitivity to patent risks and clinical trial results, helping to distinguish fundamental undervaluation from business stagnation.

Karo sapa Exelixis, Inc. saingan

GMAB (genmab.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S NUVL (Nuvalent)|Multiplikator rega marang pendapatan Kymera Therapeutics, Inc.|IDEAYA Bio - Multiplikator P/S|Rega marang dodolan Enliven Corp|ORIC (ORIC Pharmaceuticals) - Kapitalisasi marang pendapatan|RLAY: Kapitalisasi marang volume dodolan|NRIX (Nurix Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Tyra Biosciences Inc TYRA|Multiplikator P/S VSTM|Monte Rosa Corp - Rasio kapitalisasi marang pendapatan|Cullinan Therapeutics - Kapitalisasi marang pendapatan|Rasio kapitalisasi pasar marang pendapatan IMRX|CCCC: Kapitalisasi marang pendapatan|Black Diamond Therapeutics, Inc. - Kapitalisasi marang volume dodolan|RPTX: Multiplikator P/S|PMV Pharmaceuticals, Inc - Rasio kapitalisasi pasar marang pendapatan|KPTI (Karyopharm Therapeutics, Inc.) - Multiplikator P/S|Rega marang dodolan Propanc Biopharma, Inc. PPCB|Rasio rega marang pendapatan Bio Green Med Solution (BGMS)|AADI (aadibio.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ALRN (Aileron Therapeutics, Inc.)|Multiplikator P/S Blueprint Medicines Corp. BPMC|GLYC - Rasio rega marang pendapatan|Rasio rega marang dodolan SWTX